(HealthDay News) — A prognostic model has been developed and validated which has adequate discrimination for major outcomes in type 1 diabetes, according to a study published online August 28 in Diabetologia.

Sabita S. Soedamah-Muthu, PhD, from Wageningen University in the Netherlands, and colleagues developed a prognostic model and quantified its performance in independent cohorts. The authors analyzed data from 1,973 participants with type 1 diabetes from the EURODIAB Prospective Complications Study who were followed for seven years. Factors that were found to be prognostic for major outcomes were combined in a model, whose performance was tested in three prospective cohorts: the Pittsburgh Epidemiology of Diabetes Complications study (EDC; 554 participants); the Finnish Diabetic Nephropathy study (FinnDiane; 2,999 participants); and the Coronary Artery Calcification in Type 1 Diabetes study (CACTI, 580 participants). Major coronary heart disease, stroke, end-stage renal failure, amputations, blindness, and all-cause death were included as major outcomes.

The researchers found that during follow-up, 95 patients from EURODIAB developed major outcomes. Hemoglobin A1c, waist-to-hip ratio, albumin/creatinine ratio, and high-density lipoprotein cholesterol level were identified as prognostic factors. The model had adequate discriminative ability, with a concordance statistic (C-statistic) of 0.74. Similar discrimination was seen in the validation cohorts, with C-statistics of 0.79, 0.82, and 0.73 for EDC, FinnDiane, and CACTI, respectively.

“Such a prognostic model may be helpful in clinical practice and for risk stratification in clinical trials,” the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)